Avacta Therapeutics (LSE:AVCT) has announced a leadership transition that will see non-executive director Richard Hughes assume the role of non-executive chairman following the company’s annual general meeting on 22 June 2026.
Hughes will succeed Shaun Chilton, who is stepping down from the board after serving as chairman. Although leaving his board position, Chilton will continue to support the company as an adviser to the chief executive officer and directors, helping to maintain continuity as Avacta advances its clinical development programmes.
The company also confirmed that it is searching for a non-executive deputy chairman and senior independent director with significant international biotechnology experience. The recruitment process forms part of a broader effort to strengthen governance and support the next phase of growth as Avacta continues to develop its oncology portfolio.
Operationally, the group remains focused on progressing two cancer drug candidates based on its proprietary pre|CISION platform through clinical trials. At the same time, management is expanding discussions with potential pharmaceutical partners as it seeks to maximise the commercial potential of its technology and development pipeline.
Avacta’s outlook continues to be influenced by the financial demands of clinical-stage drug development. The company remains loss-making and is managing ongoing cash burn and balance sheet pressures associated with advancing multiple programmes. However, technical indicators have been more supportive, with the shares trading above longer-term moving averages and showing positive momentum signals. Recent clinical progress and efforts to improve cash management provide additional encouragement, although future financing requirements, partnership negotiations and development timelines remain important factors for investors to monitor.
More about Avacta Group plc
Avacta Therapeutics is a clinical-stage biotechnology company focused on developing innovative cancer treatments. The company’s research is centred on its proprietary pre|CISION platform, which is designed to activate therapeutic agents within the tumour microenvironment while limiting exposure to healthy tissue.
By targeting fibroblast activation protein (FAP), the technology aims to improve the delivery of highly potent cancer therapies, potentially reducing side effects and enabling more effective dosing. Avacta is advancing a pipeline of oncology candidates intended to address unmet medical needs across a range of cancer indications.
Leave a Reply